TIMM8A Antibody

What is TIMM8A and why is it important in biological research?

TIMM8A (Translocase of Inner Mitochondrial Membrane 8A) is a protein-coding gene located on the X chromosome. The gene product is a key component of the TIMM complex, which is responsible for importing nuclear-encoded proteins into the mitochondria. This process is crucial for proper mitochondrial function . TIMM8A is important in biological research for several reasons. It plays a critical role in mitochondrial protein import, making it essential for understanding mitochondrial biology. Dysfunction of TIMM8A has been linked to various mitochondrial diseases, including deafness-dystonia syndrome and Mohr-Tranebjaerg syndrome . Recent research has associated TIMM8A with cancer progression and poor prognosis in breast cancer (BRCA) and uterine corpus endometrial cancer (UCEC) . Additionally, TIMM8A may influence immune cell function and infiltration in tumor microenvironments . Studying TIMM8A helps researchers understand fundamental mitochondrial processes and their roles in both normal physiology and disease states.

What are the available types of TIMM8A antibodies for research?

Several types of TIMM8A antibodies are available for research purposes, each with specific characteristics and applications. Rabbit polyclonal antibodies include Proteintech rabbit polyclonal TIMM8A antibody (11179-1-AP) and TIMM8A Rabbit Polyclonal Antibody (CAB9811) . These antibodies recognize multiple epitopes on the TIMM8A protein and are validated for various applications. Mouse monoclonal antibodies such as TIMM8A Antibody (2F11) - Azide and BSA Free (H00001678-M01) offer high specificity by targeting a single epitope . These antibodies vary in their host species, clonality, and validated applications, providing researchers with options based on their specific experimental needs. The sequence coverage of these antibodies typically spans the full TIMM8A protein sequence, which corresponds to amino acids 1-97 of human TIMM8A (NP_004076.1) .

What are the primary applications of TIMM8A antibodies in laboratory research?

TIMM8A antibodies are utilized in multiple laboratory techniques and applications. Western Blot (WB) is a primary application for detecting TIMM8A protein expression in cell and tissue lysates, with recommended dilutions ranging from 1:500 to 1:2000 depending on the specific antibody . Immunofluorescence/Immunocytochemistry (IF/ICC) is used for visualizing the subcellular localization of TIMM8A, typically at dilutions of 1:50 to 1:200 . Enzyme-Linked Immunosorbent Assay (ELISA) provides quantitative detection of TIMM8A protein . Immunohistochemistry-Paraffin (IHC-P) detects TIMM8A expression in formalin-fixed paraffin-embedded tissue sections, used at concentrations around 3 μg/ml . Immunoprecipitation (IP) is employed for isolating TIMM8A protein complexes and studying protein-protein interactions . These diverse applications enable researchers to study TIMM8A expression, localization, and interactions in various experimental contexts, contributing to our understanding of its role in mitochondrial biology and disease.

How does TIMM8A function in mitochondrial biology?

TIMM8A functions as a critical component of the mitochondrial protein import machinery. It localizes to the intermembrane space in mitochondria and is specifically associated with the peripheral side of the mitochondrial inner membrane . TIMM8A forms a complex with TIMM13 (the TIMM8A-TIMM13 complex), which plays a specialized role in protein import . This complex mediates the import of specific nuclear-encoded proteins into the mitochondrial inner membrane, including targets such as TIMM23, SLC25A12/ARALAR1, and SLC25A13/ARALAR2 . This function differs from the TIMM9-TIMM10 complex, which handles a broader range of proteins . Beyond protein import, TIMM8A has been implicated in mitochondrial morphology and fission processes, which are essential for maintaining mitochondrial health and function . Dysfunction of TIMM8A disrupts these protein import processes, potentially leading to mitochondrial dysfunction and associated diseases such as Mohr-Tranebjaerg syndrome and deafness-dystonia syndrome .

What is the proper storage and handling of TIMM8A antibodies to maintain efficacy?

To maintain the efficacy of TIMM8A antibodies, researchers should follow specific storage and handling guidelines. Antibodies should be stored at -20°C or -80°C for long-term preservation, avoiding repeated freeze-thaw cycles that can degrade antibody quality . Upon receipt, it's recommended to aliquot the antibody into smaller volumes based on expected usage to minimize freeze-thaw cycles and prevent contamination of the stock solution . TIMM8A antibodies are typically shipped with polar packs for temperature maintenance, and upon receipt, should be immediately transferred to recommended storage conditions . Some antibody formulations may contain preservatives such as sodium azide, while others are specifically formulated as "Azide-free" for certain applications . TIMM8A antibodies are often formulated in 1x PBS, pH 7.4, and researchers should be aware of the antibody concentration, which may vary between lots . Working dilutions should be prepared immediately before use and not stored for extended periods to maintain optimal antibody performance . Following these guidelines helps ensure antibody stability and reliable experimental results.

How can TIMM8A antibodies be utilized to study mitochondrial diseases?

TIMM8A antibodies are valuable tools for investigating mitochondrial diseases, particularly those associated with TIMM8A dysfunction such as Mohr-Tranebjaerg syndrome/Deafness-Dystonia-Optic Neuronopathy (DDON) syndrome . For mutation analysis, TIMM8A antibodies can be used to assess protein expression in patient-derived cells, helping determine if mutations result in protein absence, reduction, or altered localization . In a study of a novel TIMM8A variant that altered the initiation codon, western blotting with TIMM8A antibodies confirmed the loss of protein expression . For functional studies, researchers can utilize TIMM8A antibodies to investigate how mutations affect protein-protein interactions through co-immunoprecipitation with TIMM8A antibodies, revealing changes in complex formation with TIMM13 and other partners . This approach helps elucidate the molecular mechanisms underlying disease pathology. Since TIMM8A has been linked to mitochondrial morphology and fission, immunofluorescence studies using TIMM8A antibodies combined with mitochondrial markers can reveal structural abnormalities, connecting TIMM8A dysfunction to broader mitochondrial pathology . TIMM8A antibodies can also be used in protein import assays to measure mitochondrial protein import efficiency, comparing import rates in normal versus disease conditions to quantify functional deficits . When testing potential therapeutics, TIMM8A antibodies can serve as tools to measure target engagement, with restoration of normal TIMM8A levels or localization monitored as a marker of treatment efficacy.

What are the best practices for optimizing TIMM8A antibody use in Western blot applications?

Optimizing TIMM8A antibody use in Western blot applications requires attention to several key factors. For sample preparation, proper cell fractionation is crucial since TIMM8A is specifically localized to mitochondria . Including mitochondrial enrichment steps enhances detection sensitivity, and appropriate lysis buffers that preserve mitochondrial proteins should be used . For gel selection, TIMM8A is a small protein (~11 kDa), requiring higher percentage gels - 15% SDS-PAGE gels are recommended for optimal resolution . Gradient gels (10-20%) can be used for simultaneous analysis of TIMM8A and larger proteins. Transfer conditions should be optimized for small proteins, with shorter transfer times at higher voltage often working better than overnight transfers . Nitrocellulose membranes are recommended for optimal binding of small proteins. For blocking conditions, 5% nonfat powdered milk in TBS-T solution for 1 hour at room temperature has been validated . For antibody dilution and incubation, Proteintech rabbit polyclonal TIMM8A antibody can be used at 1:1,000 dilution with 24-hour incubation at 4°C , while TIMM8A Rabbit Polyclonal Antibody (CAB9811) works at 1:500 - 1:2000 dilution , and TIMM8A Antibody (2F11) at 1:500 dilution . For secondary antibodies, anti-rabbit-HRP at 1:1,000 dilution with 1-hour incubation at room temperature is effective . Positive controls should include U-87MG cell lysates or TIMM8A-transfected 293T cells showing a band at 11 kDa .

How can researchers validate TIMM8A antibody specificity in their experimental models?

Validating antibody specificity is crucial for ensuring reliable experimental results. For TIMM8A antibodies, researchers can employ several approaches. Genetic validation involves comparing antibody reactivity in wild-type versus TIMM8A-depleted samples through knockdown/knockout methods, and using TIMM8A-transfected cells (e.g., 293T cells) as positive controls . The expected band at 11 kDa should disappear in knockouts or be enhanced in overexpression models . Immunoblotting validation can be performed using different TIMM8A antibodies targeting distinct epitopes, where concordant results with different antibodies increase confidence in specificity . For tissue/cell type specificity validation, researchers should test antibody reactivity across tissues with known TIMM8A expression patterns, with results aligning with established expression data from mRNA studies . U-87MG cells have been validated as positive controls for TIMM8A detection . When validating subcellular localization, TIMM8A should co-localize with mitochondrial markers in immunofluorescence studies, confirming its expected localization to the mitochondrial intermembrane space . Non-specific antibodies may show diffuse or inappropriate subcellular distribution. For cross-species reactivity assessment, researchers should confirm reactivity with the species of interest if working with non-human models. Available TIMM8A antibodies have been validated for human, mouse, and rat samples . These validation strategies ensure that experimental results accurately reflect TIMM8A biology rather than antibody artifacts.

What methods are most effective for studying TIMM8A-TIMM13 complex interactions?

Studying the TIMM8A-TIMM13 complex interactions requires specialized techniques to capture and analyze these protein-protein interactions. Co-Immunoprecipitation (Co-IP) is a primary method where TIMM8A antibodies are used to pull down the complex from mitochondrial extracts, followed by Western blot with TIMM13 antibodies (e.g., Proteintech rabbit polyclonal TIMM13 antibody at 1:500 dilution) . This approach confirms direct interaction between TIMM8A and TIMM13. For higher resolution in situ studies, Proximity Ligation Assay (PLA) can be employed using both TIMM8A and TIMM13 antibodies from different species to visualize protein interactions with single-molecule resolution. Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) separates native protein complexes while maintaining their interactions, allowing Western blotting with TIMM8A and TIMM13 antibodies to identify the complex and reveal its molecular weight of approximately 70 kDa . For functional studies, import assays can measure the import efficiency of known TIMM8A-TIMM13 substrates (TIMM23, SLC25A12/ARALAR1, SLC25A13/ARALAR2), comparing import rates in systems with normal versus disrupted complex formation . This links complex formation to functional outcomes. Mutational analysis involves introducing mutations to TIMM8A and assessing their impact on TIMM13 binding, mapping critical interaction domains and studying disease-associated mutations for their effects on complex formation . These complementary methods provide insights into the composition, dynamics, and function of the TIMM8A-TIMM13 complex in mitochondrial protein import.

How does TIMM8A expression correlate with immune cell infiltration in cancer models?

Research has revealed significant correlations between TIMM8A expression and immune cell infiltration in cancer, particularly in breast cancer (BRCA) and uterine corpus endometrial cancer (UCEC) . In BRCA, TIMM8A expression shows significant positive correlations with infiltrating levels of B cells (r = 0.174, P = 3.43e−08), Th2 CD4+ T cells (r = 0.564, P = 1.89e−84), CD8+ T cells (r = 0.147, P = 3.02e−06), dendritic cells (r = 0.163, P = 2.31e−07), macrophages (r = 0.254, P = 4.83e−16), and neutrophils (r = 0.313, P = 4.57e−24) . These positive correlations suggest that higher TIMM8A expression is associated with increased immune infiltration in BRCA. In UCEC, TIMM8A expression shows a positive correlation with Th2-type CD4+ T cells (r = 0.329, P = 1.78e−03) but negative correlations with CD8+ T cells (r = −0.416, P = 5.61e−05), macrophages (r = −0.338, P = 1.30e−03), dendritic cells (r = −0.328, P = 1.38e−03), NK cells (r = −0.247, P = 2.01e−02), and regulatory T cells (r = −0.376, P = 3.07e−04) . These mixed correlations suggest a more complex role in UCEC immune environments. Notably, Th2 CD4+ T cells show positive correlation with TIMM8A in both cancer types, suggesting they may be a common pathway by which TIMM8A influences cancer progression . TIMM8A expression correlates with PD-L1 (CD274) in both cancer types, and with various cytokines including IL-10 . These findings suggest TIMM8A may be a potential biomarker for predicting immunotherapy response, particularly anti-PD-L1 therapy efficacy in BRCA and UCEC.

What are the considerations when selecting between polyclonal and monoclonal TIMM8A antibodies?

When selecting between polyclonal and monoclonal TIMM8A antibodies, researchers should consider several factors that impact experimental outcomes. For epitope recognition, polyclonal antibodies (e.g., Proteintech 11179-1-AP, CAB9811) recognize multiple epitopes on the TIMM8A protein, offering greater detection sensitivity, especially for low-abundance targets . In contrast, monoclonal antibodies (e.g., TIMM8A Antibody 2F11) recognize a single epitope with high specificity and provide more consistent results across different lots . For application suitability, in Western blotting, both antibody types work well, with polyclonals potentially offering higher sensitivity while monoclonals typically produce cleaner backgrounds with less optimization . For immunohistochemistry/immunofluorescence, polyclonals may provide stronger signals in fixed tissues, while monoclonals often yield more specific localization patterns . Regarding experimental variability, polyclonal antibodies may exhibit significant lot-to-lot variation requiring revalidation when purchasing new lots, whereas monoclonal antibodies offer more consistent performance across batches and better reproducibility for longitudinal studies . When considering target state, some antibodies perform better with denatured proteins (for Western blot), while others recognize conformational epitopes in native states (for IP, IF) . Species reactivity also varies: CAB9811 and Proteintech 11179-1-AP react with human, mouse, and rat samples, while monoclonal 2F11 is specific to human samples . The optimal choice ultimately depends on the specific experimental goals, techniques, and biological questions being addressed.

How can researchers troubleshoot non-specific binding when using TIMM8A antibodies?

Non-specific binding is a common challenge when working with antibodies. For TIMM8A antibodies, researchers can implement several troubleshooting strategies. For background reduction, optimize blocking conditions by testing different blocking agents (5% milk, 3-5% BSA) and increasing blocking time from 1 hour to overnight at 4°C . Modify washing protocols by increasing the number of washes (5-6 times for 5-10 minutes each) and adding 0.1-0.3% Triton X-100 or Tween-20 to wash buffers for more stringent washing. Adjust antibody concentrations by testing a dilution series to find the optimal concentration, considering ranges beyond the recommended 1:500-1:2000 for TIMM8A antibodies . For sample-specific optimizations, especially for mitochondrial proteins like TIMM8A, perform subcellular fractionation to enrich mitochondria and compare whole cell lysates to mitochondrial fractions . This helps distinguish specific mitochondrial signals from non-specific cytoplasmic staining. For Western blot protocol modifications, use higher percentage gels (15%) for the ~11 kDa TIMM8A protein, and include positive controls like U-87MG cell lysates or TIMM8A-transfected cells showing the expected 11 kDa band . For immunohistochemistry, optimize antigen retrieval methods and adjust antibody concentration (validated at 3 μg/ml for IHC-P) . Consider secondary antibody modifications by testing secondary antibodies from different manufacturers, using highly cross-adsorbed secondaries to reduce species cross-reactivity, and matching the secondary to the primary host species (anti-rabbit for rabbit polyclonals) . For data validation, compare results with alternative detection methods like RT-qPCR for TIMM8A mRNA expression, and use multiple TIMM8A antibodies targeting different epitopes to increase confidence in specificity .

What are the latest research findings connecting TIMM8A to cancer immunology?

Recent research has revealed important connections between TIMM8A and cancer immunology, particularly in breast cancer (BRCA) and uterine corpus endometrial cancer (UCEC) . TIMM8A has emerged as a prognostic biomarker, with expression significantly associated with poor prognosis in BRCA and UCEC, suggesting it may contribute to cancer progression through immune modulation . Immune cell infiltration studies show that in BRCA, TIMM8A expression positively correlates with infiltration of multiple immune cell types, including Th2 CD4+ T cells (r = 0.564, P = 1.89e−84), CD8+ T cells (r = 0.147, P = 3.02e−06), and macrophages (r = 0.254, P = 4.83e−16) . In UCEC, TIMM8A shows opposing correlations: positive with Th2 CD4+ T cells but negative with CD8+ T cells and other immune cells . Notably, Th2 CD4+ T cells show consistent positive correlation with TIMM8A across both cancer types, suggesting they may be a common pathway through which TIMM8A contributes to poor prognosis . TIMM8A expression correlates with immune checkpoint molecules, showing positive correlation with PD-L1 (CD274) and CD80 in both cancer types, suggesting TIMM8A may influence response to checkpoint blockade therapies . In terms of immune evasion mechanisms, TIMM8A is associated with potential T cell exclusion, with myeloid-derived suppressor cells (MDSC) and tumor-associated M2 macrophages (TAM M2) with high TIMM8A expression potentially promoting immune evasion . This suggests TIMM8A could be a biomarker for predicting immunotherapy resistance. TIMM8A also shows cytokine correlations, positively correlating with IL-10 in both cancer types, which is known to modulate immune responses in the tumor microenvironment .

How can TIMM8A antibodies be used to investigate mitochondrial morphology and fission?

TIMM8A antibodies can be powerful tools for investigating mitochondrial morphology and fission through several methodological approaches . For immunofluorescence microscopy, researchers can use a co-staining approach with TIMM8A antibodies alongside mitochondrial markers (e.g., MitoTracker, TOMM20) to visualize TIMM8A localization relative to mitochondrial structures . This provides insights into how TIMM8A distribution relates to mitochondrial network organization. For super-resolution microscopy techniques such as STORM/PALM, specialized antibody preparations can overcome the diffraction limit of conventional microscopy, allowing visualization of TIMM8A distribution at nanometer resolution and potentially revealing TIMM8A localization at sites of mitochondrial constriction during fission events . For functional assays combining imaging and biochemistry, researchers can quantify mitochondrial fragmentation by measuring mitochondrial morphology parameters following TIMM8A manipulation, comparing wild-type, TIMM8A-depleted, and TIMM8A-overexpressing cells . This approach can quantify parameters like mitochondrial length, branching, and interconnectivity. Correlation studies with fission proteins can use TIMM8A antibodies alongside antibodies against known fission proteins (DRP1, FIS1) for co-immunoprecipitation or sequential imaging . For mitochondrial isolation and fractionation, TIMM8A antibodies can be used in Western blots of isolated mitochondria to compare protein levels in mitochondrial subfractions and correlate TIMM8A levels with mitochondrial fragmentation states . In perturbation studies, TIMM8A antibodies can confirm knockdown/overexpression efficiency and measure consequent changes in mitochondrial morphology, establishing causality between TIMM8A levels and morphological changes . These methodologies provide complementary approaches to understand TIMM8A's role in mitochondrial dynamics.

What are the current challenges in studying TIMM8A mutations using antibody-based approaches?

Studying TIMM8A mutations using antibody-based approaches presents several challenges that researchers must navigate . Epitope alterations in mutant proteins represent a significant challenge, as mutations may alter or eliminate the epitope recognized by the antibody . Methodological solutions include using multiple antibodies targeting different regions of TIMM8A and selecting antibodies targeting preserved regions for known mutations . In cases of Mohr-Tranebjaerg syndrome with TIMM8A mutations, antibodies targeting N-terminal epitopes may fail to detect truncated proteins . Protein expression level detection presents another challenge, as many TIMM8A mutations cause complete absence of protein rather than altered function . In a study of a novel TIMM8A variant altering the initiation codon, western blotting confirmed complete loss of protein expression . Distinguishing specific mutations is difficult because antibodies typically cannot distinguish between wild-type and point-mutated proteins . Advanced approaches include developing mutation-specific antibodies for common mutations or combining immunoprecipitation with mass spectrometry for mutation identification . Subcellular localization assessment of mutant proteins is challenging because mutations may alter TIMM8A localization without affecting antibody recognition . Methodological strategies include combining subcellular fractionation with Western blotting and using high-resolution imaging to track subtle localization changes . Detecting altered TIMM8A-TIMM13 complex formation in mutants represents another challenge, addressed through native gel electrophoresis followed by Western blotting or co-immunoprecipitation with TIMM13 antibodies . Technical challenges with small proteins are significant since TIMM8A is a small protein (~11 kDa), requiring high-percentage gels (15% SDS-PAGE) and optimized transfer conditions .